THREE INVESTIGATORS were named recipients of the 2015 Paul Marks Prize for Cancer Research by Memorial Sloan Kettering Cancer Center. The award recognizes investigators age 45 or younger for their efforts in advancing cancer research.
City of Hope and Sorrento Therapeutics Inc. formed a company, LA Cell Inc., to focus on the development of cell-penetrating antibody therapies. LA Cell has exclusively licensed technology developed at City of Hope that enables modified monoclonal antibodies to penetrate into cells and target disease-causing molecules.
LORENZ STUDER, director of the Center for Stem Cell Biology at Memorial Sloan Kettering Cancer Center, was named a fellow by the MacArthur Foundation.
UbiVac formed a collaboration with Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop new preclinical and clinical versions of UbiVac's proprietary DRibble immunotherapy for use in preclinical studies of oral cancer.
Aspen Park Pharmaceuticals Inc. acquired worldwide rights to APP-111, first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer, from The Ohio State University, through the Ohio State Innovation Foundation.
FDA approved Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
Telotristat etiprate showed clinical benefit in treating carcinoid syndrome in cancer patients not adequately controlled by long-acting somatostatin analog therapy, the current standard of care, according to data from the phase III TELESTAR study.
A phase II study of Cyramza (ramucirumab) in combination with docetaxel met its primary endpoint, demonstrating a statistically significant increase in progression-free survival for patients with locally advanced or metastatic urothelial carcinoma who failed prior platinum-based therapy.
Two separate papers published in the New England Journal of Medicine showed that imetelstat demonstrated disease-modifying activities in phase II studies of myelofibrosis and essential thrombocythemia.
